The experimental drug neflamapimod reduced a key biomarker of neurodegeneration, which correlated with a slowing of cognitive and functional decline in patients with DLB, phase 2b trial results show.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/novel-med-tied-slowed-decline-lewy-body-dementia-2025a1000yls?src=rss
Author :
Publish date : 2025-12-10 09:16:00
Copyright for syndicated content belongs to the linked Source.